First Time Loading...

Amneal Pharmaceuticals Inc
NYSE:AMRX

Watchlist Manager
Amneal Pharmaceuticals Inc Logo
Amneal Pharmaceuticals Inc
NYSE:AMRX
Watchlist
Price: 6.765 USD 8.94% Market Closed
Updated: May 4, 2024

Amneal Pharmaceuticals Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amneal Pharmaceuticals Inc
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Amneal Pharmaceuticals Inc
NYSE:AMRX
Operating Income
$274.8m
CAGR 3-Years
24%
CAGR 5-Years
-1%
CAGR 10-Years
27%
Johnson & Johnson
NYSE:JNJ
Operating Income
$23.4B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$10.5B
CAGR 3-Years
14%
CAGR 5-Years
6%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Operating Income
$13.1B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
-3%
Merck & Co Inc
NYSE:MRK
Operating Income
$6.6B
CAGR 3-Years
-10%
CAGR 5-Years
-11%
CAGR 10-Years
-2%
Eli Lilly and Co
NYSE:LLY
Operating Income
$10.3B
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
6%

See Also

What is Amneal Pharmaceuticals Inc's Operating Income?
Operating Income
274.8m USD

Based on the financial report for Dec 31, 2023, Amneal Pharmaceuticals Inc's Operating Income amounts to 274.8m USD.

What is Amneal Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
27%

Over the last year, the Operating Income growth was 38%. The average annual Operating Income growth rates for Amneal Pharmaceuticals Inc have been 24% over the past three years , -1% over the past five years , and 27% over the past ten years .